The risks of concurrent treatment with tenofovir and aminoglycosides in patients with HIV-associated tuberculosis

  • C Kenyon
  • N Wearne
  • R Burton
  • G Meintjes

Abstract

The South African public sector antiretroviral treatment (ART) guidelines have recently been changed to include tenofovir in the first-line regimen.1 Injectable drugs from the aminoglycoside class are part of the intensive phase of regimen 2 tuberculosis (TB) treatment and the multidrug-resistant (MDR) TB treatment regimen in the South African TB programme. We wish to draw the attention of clinicians managing patients with HIVassociated TB to the potential dangers of concurrent administration of these drugs. We present two illustrative cases.
Section
Articles

Journal Identifiers


eISSN: 2078-6751
print ISSN: 1608-9693